The effectiveness and safety of dabigatran for stroke prevention in atrial fibrillation (SPAF)
demonstrated in RE-LY needs to be confirmed in daily care. To evaluate treatment …

Background and purpose GLORIA-AF is a large, global, prospective registry program of
newly diagnosed atrial fibrillation (AF) patients with≥ 1 stroke risk factors. We describe the …

Background—During follow-up of between 1 and 3 years in the Randomized Evaluation of
Long-term Anticoagulation Therapy (RE-LY) trial, 2 doses of dabigatran etexilate were …

The RE-LY study demonstrated the safety and efficacy of dabigatran relative to warfarin for
stroke prevention in non-valvular atrial fibrillation. It is important to further evaluate safety …

Background Dabigatran, an oral direct thrombin inhibitor, possesses several advantages
over warfarin that can in principle simplify the management of stroke prevention in atrial …

Dabigatran is approved for stroke risk reduction in patients with nonvalvular atrial fibrillation
(NVAF). Data from diverse clinical practice settings will help establish whether the risk …

In the RE-LY trial dabigatran 150 mg twice daily (D150) showed significantly fewer strokes,
and 110 mg (D110) significantly fewer major bleeding events (MBE) compared to well …

Background The recent availability of dabigatran, a novel oral anticoagulant, provided a new
treatment option for stroke prevention in atrial fibrillation beyond warfarin, the main therapy …

Background—Recent studies have investigated alternatives to warfarin for stroke
prophylaxis in patients with atrial fibrillation (AF), but whether these alternatives are cost …

Objectives: The aim of this study was to assess the efficacy and safety in an “everyday
clinical practice” population of anticoagulant-naïve patients with atrial fibrillation (AF) treated …